Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients
- Wednesday, August 3, 2022, 4:04
- Environment
- Add a comment
— ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active metabolite ASC10-A, which is the same active metabolite of molnupiravir — Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10…
About the Author
adminasapcorp has written 39302 stories on this site.